225 related articles for article (PubMed ID: 38428427)
1. Mediator complex subunit 1 architects a tumorigenic Treg cell program independent of inflammation.
Chaudhuri SM; Weinberg SE; Wang D; Yalom LK; Montauti E; Iyer R; Tang AY; Torres Acosta MA; Shen J; Mani NL; Wang S; Liu K; Lu W; Bui TM; Manzanares LD; Dehghani Z; Wai CM; Gao B; Wei J; Yue F; Cui W; Singer BD; Sumagin R; Zhang Y; Fang D
Cell Rep Med; 2024 Mar; 5(3):101441. PubMed ID: 38428427
[TBL] [Abstract][Full Text] [Related]
2. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
3. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity.
Kalim KW; Yang JQ; Wunderlich M; Modur V; Nguyen P; Li Y; Wen T; Davis AK; Verma R; Lu QR; Jegga AG; Zheng Y; Guo F
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36427906
[TBL] [Abstract][Full Text] [Related]
4. Med1 Controls Effector CD8
Jiao A; Liu H; Ding R; Zheng H; Zhang C; Feng Z; Lei L; Wang X; Su Y; Yang X; Sun C; Zhang L; Bai L; Sun L; Zhang B
J Immunol; 2022 Sep; 209(5):855-863. PubMed ID: 36130132
[TBL] [Abstract][Full Text] [Related]
5. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
6. Targeting Treg cells in cancer immunotherapy.
Tanaka A; Sakaguchi S
Eur J Immunol; 2019 Aug; 49(8):1140-1146. PubMed ID: 31257581
[TBL] [Abstract][Full Text] [Related]
7. Graded Foxo1 activity in Treg cells differentiates tumour immunity from spontaneous autoimmunity.
Luo CT; Liao W; Dadi S; Toure A; Li MO
Nature; 2016 Jan; 529(7587):532-6. PubMed ID: 26789248
[TBL] [Abstract][Full Text] [Related]
8. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
9. Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.
Li X; Acuff NV; Peeks AR; Kirkland R; Wyatt KD; Nagy T; Watford WT
J Biol Chem; 2016 Aug; 291(32):16802-15. PubMed ID: 27261457
[TBL] [Abstract][Full Text] [Related]
10. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy.
Gyori D; Lim EL; Grant FM; Spensberger D; Roychoudhuri R; Shuttleworth SJ; Okkenhaug K; Stephens LR; Hawkins PT
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875321
[TBL] [Abstract][Full Text] [Related]
11. Attenuation of CD4
Kunisada Y; Eikawa S; Tomonobu N; Domae S; Uehara T; Hori S; Furusawa Y; Hase K; Sasaki A; Udono H
EBioMedicine; 2017 Nov; 25():154-164. PubMed ID: 29066174
[TBL] [Abstract][Full Text] [Related]
12. Transient Depletion of Foxp3
Watts D; Janßen M; Jaykar M; Palmucci F; Weigelt M; Petzold C; Hommel A; Sparwasser T; Bonifacio E; Kretschmer K
Front Immunol; 2021; 12():720133. PubMed ID: 34447385
[TBL] [Abstract][Full Text] [Related]
13. Bcl10 is required for the development and suppressive function of Foxp3
Yang D; Zhao X; Lin X
Cell Mol Immunol; 2021 Jan; 18(1):206-218. PubMed ID: 31595055
[TBL] [Abstract][Full Text] [Related]
14. Effect of Med1 on T cell development and CD4
Zheng H; Jiao A; Liu H; Lei L; Ding R; Feng Z; Zhang D; Zhang L; Zhang B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1296-1303. PubMed ID: 38044640
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T-cell development in the tumor microenvironment.
Itahashi K; Irie T; Nishikawa H
Eur J Immunol; 2022 Aug; 52(8):1216-1227. PubMed ID: 35879813
[TBL] [Abstract][Full Text] [Related]
16. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.
Lee YL; Ito K; Pi WC; Lin IH; Chu CS; Malik S; Cheng IH; Chen WY; Roeder RG
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33542097
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of human FoxP3
Attias M; Al-Aubodah T; Piccirillo CA
Clin Exp Immunol; 2019 Jul; 197(1):36-51. PubMed ID: 30864147
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer.
Moo-Young TA; Larson JW; Belt BA; Tan MC; Hawkins WG; Eberlein TJ; Goedegebuure PS; Linehan DC
J Immunother; 2009 Jan; 32(1):12-21. PubMed ID: 19307989
[TBL] [Abstract][Full Text] [Related]
19. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
20. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
